ClinicalTrials.gg
CompletedNCT04697628innovaTV 301Updated Feb 24, 2026Results posted

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

A Phase 3 interventional study of tisotumab vedotin and topotecan in Cervical Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Completed at 211 sites in 25 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
502
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Uterine Cervical Neoplasms by Pfizer — 3 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Pfizer.

Enrollment
2nd of 16
502 · median 122
Started
2021
with 2 others
Phase 3
Only one
of the 17
Registered
13th of 17
by date

Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 3, and was the 13th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 17 studies in Uterine Cervical Neoplasms by Pfizer are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Uterine Cervical Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).

Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.

03

Conditions studied

  • Cervical Cancer

Keywords

  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has recurrent or cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:
  • Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either:

    • paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or
    • paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or
    • paclitaxel + topotecan/nogitecan + bevacizumab + anti-PD-(L)1 agent
  • Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the participant was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required.
  • Has received 1 or 2 prior systemic therapy regimens for recurrent and/or metastatic cervical cancer. Chemotherapy administered in the or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for r/mCC cancer should be counted.
  • according to v1.1 as assessed by the investigator.
  • Has performance status of 0 or 1 prior to randomization.
  • Has of at least 3 months.

Exclusion criteria

Exclusion Criteria

  • Has primary neuroendocrine, lymphoid, sarcomatoid, or other histologies not mentioned as part of the inclusion criteria above.
  • Has bleeding issues or risks. This includes known past or current coagulation defects leading to an increased risk of bleeding; diffuse alveolar hemorrhage from vasculitis; known bleeding diathesis; ongoing major bleeding; trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within 8 weeks of trial entry.
  • Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke ( >1 month prior to screening is allowed).
  • Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (e.g. Wagner syndrome, atopic keratoconjunctivitis, disease affecting the eyes), ocular Stevens-Johnson syndrome or toxic epidermal necrolysis, mucus pemphigoid, and participants with penetrating ocular transplants. Cataracts alone is not an exclusion criterion.
  • Major surgery within 4 weeks or minor surgery within 7 days prior to the first study treatment administration.
  • Peripheral neuropathy ≥grade 2.
  • Any prior treatment with monomethyl auristatin E (MMAE)-containing drugs.

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
502 participants (actual)

Study arms

  • Experimental
    Tisotumab vedotin

    Tisotumab vedotin monotherapy

    Drug: tisotumab vedotin

  • Active comparator
    Chemotherapy

    Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)

    Drug: topotecan · Drug: vinorelbine · Drug: gemcitabine · Drug: irinotecan · Drug: pemetrexed

Interventions

  • 2.0 mg/kg every 3 weeks (Q3W)

    Also known as: TIVDAK, PF-08046057

  • 1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days

  • 30 mg/m2 IV on Days 1 and 8, every 21 days

  • 1000 mg/m2 IV on Days 1 and 8, every 21 days

  • 100 or 125 mg/m2 IV weekly for 28 days, every 42 days

  • 500 mg/m2 IV on Day 1, every 21 days

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive.

    Time frame: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)

Secondary outcomes

  1. Progression Free Survival (PFS) as Assessed by Investigator

    PFS per investigator was defined as the time from the date of randomization to the first documentation of disease progression (PD) as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, or death due to any cause, whichever occurred earlier. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). Participants without evidence of radiographic disease progression or death were censored at the date of last adequate tumor assessment prior to data cut-off date or start of new anti-cancer therapy. Participants with disease progression or death that occurred after 2 or more missed scans were censored at the last adequate tumor assessment prior to missed scans. Participants without post-baseline scan data were censored at the day of randomization.

    Time frame: From the date of randomization to first documentation of PD or death due to any cause, or censoring date whichever occurred first (maximum up to 25 months)

  2. Confirmed Objective Response Rate (ORR) as Assessed by Investigator

    Confirmed objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The minimum criteria for stable disease (SD) duration are defined as ≥ 5 weeks after the date of randomization. For a response to be considered as confirmed, the subsequent response had to be at least 4 weeks after the initial response. Two-sided 95% exact confidence interval (CI) was computed using the Clopper-Pearson method.

    Time frame: From the date of randomization until date of confirmed CR or PR (maximum up to 25 months)

  3. Time-to-Response (TTR) as Assessed by the Investigator

    TTR was defined as the time from the randomization date to the date of the first confirmed objective response (CR or PR that was subsequently confirmed). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of randomization to date of date of the first confirmed objective response (maximum up to 25 months)

  4. Duration of Response (DOR) by Investigator Assessment

    DOR was defined as the time from the date of the first confirmed objective response (CR or PR that was subsequently confirmed) to the date of the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 25 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.. TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment and with onset date on or before 30 days after the last dose of study treatment.

    Time frame: From start of treatment up to 30 days after last dose of study treatment (up to 25 months)

  6. EuroQOL Five Dimensions Five Level (EQ-5D-5L) Index Score

    The EQ-5D-5L questionnaire is a 5-item self-reported measure of functioning and well-being, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems and extreme problems). Responses to the 5 items are then converted to a weighted health state index (utility score) based on values derived from general population samples. This health utility score is between 0 and 1, where 0 is death and 1 is perfect health.

    Time frame: From start of treatment until end of follow-up

  7. EQ-5D Visual Analog Scale (VAS) Scores

    EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state) ; higher scores indicate a better health state.

    Time frame: From start of treatment until end of follow-up

  8. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Total Score

    The EORTC-QLQ-C30 questionnaire is composed of 30 questions for which the answers ranges either from 1 (not at all) to 4 (very much) for items 1 to 28, or from 1 (very poor) to 7 (excellent) for items 29 to 30. The EORTC QLQ-C30 scale scores will be calculated using the EORTC QLQ-C30 Scoring Manual. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items (i.e., no item occurs in more than one scale). All of the scales and single-item measures range in score from 0 to 100, with a high scale score representing a higher response level (e.g., a high level of functioning, a high QoL, or a high level of symptomatology/problems)

    Time frame: From start of treatment until end of follow-up

  9. EORTC Quality of Life Questionnaire Cervical Cancer Module (QLQ-CX24) Total Scores

    The EORTC QLQ-CX24 questionnaire is meant for use among cervical cancer participants varying in disease stage and treatment modality. The EORTC-QLQ-CX24 questionnaire is composed of 24 questions for which the answers ranged from 1 (Not at all) to 4 (Very much). Four functional scales and 5 symptom scales will be calculated using the EORTC QLQ-CX24 Scoring Manual. The 9 scores computed from the EORTC-QLQ-CX24 questionnaire will be summarized by treatment arm using descriptive statistics.

    Time frame: From start of treatment until end of follow-up

07

Results

Posted Aug 9, 2024

Participant flow

Participants with recurrent/metastatic cervical cancer (rCC/mCC) who received 1 or 2 prior lines of systemic therapy for their recurrent or metastatic disease were included.

Participant flow — Overall Study
MilestoneTisotumab VedotinChemotherapy
Started253249
Treated250239
Completed114131
Not completed139118
Withdrew: Withdrawal by subject1723
Withdrew: Lost to follow-up04
Withdrew: On-going in study12291

Outcome measures

PrimaryOverall Survival

Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive.

Time frame:
From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)
Reported as:
Median · Months
Overall Survival
MonthsTisotumab VedotinChemotherapy
Overall Survival11.5 (9.8 to 14.9)9.5 (7.9 to 10.7)
Statistical analysis
  • Tisotumab Vedotin vs Chemotherapy · Stratified log-rank test · p = 0.0038 (Two-sided p-value calculated from stratified log-rank test.) · Cox proportional hazard: 0.70 · 95% CI 0.54 to 0.89Hazard Ratio (HR) was calculated from Cox proportional hazards model and Efron method was used in handling ties and computed using stratification factors at randomization.
SecondaryProgression Free Survival (PFS) as Assessed by Investigator

PFS per investigator was defined as the time from the date of randomization to the first documentation of disease progression (PD) as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, or death due to any cause, whichever occurred earlier. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). Participants without evidence of radiographic disease progression or death were censored at the date of last adequate tumor assessment prior to data cut-off date or start of new anti-cancer therapy. Participants with disease progression or death that occurred after 2 or more missed scans were censored at the last adequate tumor assessment prior to missed scans. Participants without post-baseline scan data were censored at the day of randomization.

Time frame:
From the date of randomization to first documentation of PD or death due to any cause, or censoring date whichever occurred first (maximum up to 25 months)
Reported as:
Median · Months
Progression Free Survival (PFS) as Assessed by Investigator
MonthsTisotumab VedotinChemotherapy
Progression Free Survival (PFS) as Assessed by Investigator4.2 (4.0 to 4.4)2.9 (2.6 to 3.1)
Statistical analysis
  • Tisotumab Vedotin vs Chemotherapy · Stratified log-rank test · p = <0.0001 (Two-sided p-value calculated from stratified log-rank test.) · Cox proportional hazard: 0.67 · 95% CI 0.54 to 0.82HR was calculated from Cox proportional hazards model and Efron method was used in handling ties and computed using stratification factors at randomization.
SecondaryConfirmed Objective Response Rate (ORR) as Assessed by Investigator

Confirmed objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The minimum criteria for stable disease (SD) duration are defined as ≥ 5 weeks after the date of randomization. For a response to be considered as confirmed, the subsequent response had to be at least 4 weeks after the initial response. Two-sided 95% exact confidence interval (CI) was computed using the Clopper-Pearson method.

Time frame:
From the date of randomization until date of confirmed CR or PR (maximum up to 25 months)
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate (ORR) as Assessed by Investigator
Percentage of participantsTisotumab VedotinChemotherapy
Confirmed Objective Response Rate (ORR) as Assessed by Investigator17.8 (13.3 to 23.1)5.2 (2.8 to 8.8)
Statistical analysis
  • Tisotumab Vedotin vs Chemotherapy · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.0 · 95% CI 2.1 to 7.6OR calculated using Cochran-Mantel-Haenszel (CMH) method controlling for stratification factors at randomization.
SecondaryTime-to-Response (TTR) as Assessed by the Investigator

TTR was defined as the time from the randomization date to the date of the first confirmed objective response (CR or PR that was subsequently confirmed). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization to date of date of the first confirmed objective response (maximum up to 25 months)
Reported as:
Median · Months
Time-to-Response (TTR) as Assessed by the Investigator
MonthsTisotumab VedotinChemotherapy
Time-to-Response (TTR) as Assessed by the Investigator1.58 (1.2 to 4.5)1.74 (1.2 to 3.9)
SecondaryDuration of Response (DOR) by Investigator Assessment

DOR was defined as the time from the date of the first confirmed objective response (CR or PR that was subsequently confirmed) to the date of the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 25 months)
Reported as:
Median · Months
Duration of Response (DOR) by Investigator Assessment
MonthsTisotumab VedotinChemotherapy
Duration of Response (DOR) by Investigator Assessment5.3 (4.2 to 8.3)5.7 (2.8 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.. TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment and with onset date on or before 30 days after the last dose of study treatment.

Time frame:
From start of treatment up to 30 days after last dose of study treatment (up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsTisotumab VedotinChemotherapy
Number of Participants With Treatment Emergent Adverse Events (TEAEs)246237
SecondaryEuroQOL Five Dimensions Five Level (EQ-5D-5L) Index Score

The EQ-5D-5L questionnaire is a 5-item self-reported measure of functioning and well-being, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems and extreme problems). Responses to the 5 items are then converted to a weighted health state index (utility score) based on values derived from general population samples. This health utility score is between 0 and 1, where 0 is death and 1 is perfect health.

Time frame:
From start of treatment until end of follow-up

Results for this outcome have not been posted.

SecondaryEQ-5D Visual Analog Scale (VAS) Scores

EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state) ; higher scores indicate a better health state.

Time frame:
From start of treatment until end of follow-up

Results for this outcome have not been posted.

SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Total Score

The EORTC-QLQ-C30 questionnaire is composed of 30 questions for which the answers ranges either from 1 (not at all) to 4 (very much) for items 1 to 28, or from 1 (very poor) to 7 (excellent) for items 29 to 30. The EORTC QLQ-C30 scale scores will be calculated using the EORTC QLQ-C30 Scoring Manual. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items (i.e., no item occurs in more than one scale). All of the scales and single-item measures range in score from 0 to 100, with a high scale score representing a higher response level (e.g., a high level of functioning, a high QoL, or a high level of symptomatology/problems)

Time frame:
From start of treatment until end of follow-up

Results for this outcome have not been posted.

SecondaryEORTC Quality of Life Questionnaire Cervical Cancer Module (QLQ-CX24) Total Scores

The EORTC QLQ-CX24 questionnaire is meant for use among cervical cancer participants varying in disease stage and treatment modality. The EORTC-QLQ-CX24 questionnaire is composed of 24 questions for which the answers ranged from 1 (Not at all) to 4 (Very much). Four functional scales and 5 symptom scales will be calculated using the EORTC QLQ-CX24 Scoring Manual. The 9 scores computed from the EORTC-QLQ-CX24 questionnaire will be summarized by treatment arm using descriptive statistics.

Time frame:
From start of treatment until end of follow-up

Results for this outcome have not been posted.

Adverse events

Collected over For All-Cause Mortality: From randomization to date of death due to any cause (up to 25 months); For SAEs and non-SAEs: From start of treatment up to 30 days after last dose of study treatment (approximately up to 25 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tisotumab Vedotin123/253 (48.6%)82/250 (32.8%)233/250 (93.2%)
Chemotherapy140/249 (56.2%)94/239 (39.3%)223/239 (93.3%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventTisotumab VedotinChemotherapy
Urinary tract infectionInfections and infestations10/25017/239
AnaemiaBlood and lymphatic system disorders2/25010/239
Febrile neutropeniaBlood and lymphatic system disorders1/2508/239
HydronephrosisRenal and urinary disorders2/2507/239
Small intestinal obstructionGastrointestinal disorders6/2501/239
Acute kidney injuryRenal and urinary disorders3/2505/239
Abdominal painGastrointestinal disorders5/2502/239
SepsisInfections and infestations5/2502/239
NeutropeniaBlood and lymphatic system disorders2/2504/239
PancytopeniaBlood and lymphatic system disorders0/2504/239
Most frequent other events
Showing 10 of 40
Most frequent other events
EventTisotumab VedotinChemotherapy
AnaemiaBlood and lymphatic system disorders56/250119/239
NauseaGastrointestinal disorders83/25093/239
ConjunctivitisInfections and infestations77/2501/239
Peripheral sensory neuropathyNervous system disorders70/2506/239
EpistaxisRespiratory, thoracic and mediastinal disorders65/2506/239
AlopeciaSkin and subcutaneous tissue disorders61/2507/239
ConstipationGastrointestinal disorders59/25039/239
Decreased appetiteMetabolism and nutrition disorders59/25041/239
NeutropeniaBlood and lymphatic system disorders15/25052/239
DiarrhoeaGastrointestinal disorders53/25036/239

Baseline characteristics

Intent-to-treat (ITT) analysis set included all randomized participants. Participants were included in the treatment group assigned at randomization regardless of any actual treatment received.

Age, Continuous
Age, Continuous(Years)Tisotumab VedotinChemotherapyTotal
Mean51.9 ± 11.851.0 ± 11.651.4 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Tisotumab VedotinChemotherapyTotal
Female253249502
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tisotumab VedotinChemotherapyTotal
Race — White122122244
Race — Asian9090180
Race — American Indian or Alaska Native7714
Race — Black or African American4610
Race — Other213
Race — Native Hawaiian or Other Pacific Islander101
Race — Not Reported191736
Race — Unknown8614
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tisotumab VedotinChemotherapyTotal
Ethinicity — Not of Hispanic or Latino/a, or Spanish Origin176177353
Ethinicity — Hispanic or Latino/a, or of Spanish Origin5250102
Ethinicity — Not Reported191736
Ethinicity — Unknown6511
08

Study locations

211 sites
  • Arizona Oncology Associates, PC - HAL
    Glendale, Arizona 85308, United States
  • Arizona Oncology Associates P.C. - NAHOA
    Phoenix, Arizona 85016, United States
  • Arizona Oncology Associates, PC - HAL
    Phoenix, Arizona 85016, United States
  • Arizona Oncology Associates, PC - HAL
    Scottsdale, Arizona 85258, United States
  • Arizona Oncology Associates, PC - HAL
    Tempe, Arizona 85284, United States
  • University of California Irvine Health
    Irvine, California 92697, United States
  • UC Irvine Health (Investigator Site File Location)
    Orange, California 92868, United States
  • University of California Irvine Health
    Orange, California 92868, United States
  • Olive View - UCLA Medical Center
    Sylmar, California 91342, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Broward Health Medical Center
    Fort Lauderdale, Florida 33316, United States
  • Georgia Cancer Center at Augusta University
    Augusta, Georgia 30912, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Norton Cancer Institute, Downtown
    Louisville, Kentucky 40202, United States
  • Norton Hospital
    Louisville, Kentucky 40202, United States
  • Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD
    Louisville, Kentucky 40207, United States
  • Norton Cancer Institute, St. Matthews Campus
    Louisville, Kentucky 40207, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Norton Women's & Children's Hospital
    Louisville, Kentucky 40207, United States
  • Willis-Knighton Cancer Center Infusion Center
    Shreveport, Louisiana 71103, United States
  • Willis-Knighton Physician Network/ Hematology-Oncology Associates
    Shreveport, Louisiana 71103, United States
  • Willis-Knighton Physician Network/WK Gynecologic Oncology Associates
    Shreveport, Louisiana 71103, United States
  • Willis-Knighton Physician Network/WK Gynecologic Oncology Associates
    Shreveport, Louisiana 71118, United States
  • Minnesota Oncology Hematology PA
    Coon Rapids, Minnesota 55433, United States
  • Minnesota Oncology Hematology, P.A
    Coon Rapids, Minnesota 55433, United States
  • Minnesota Oncology Hematology, P.A
    Edina, Minnesota 55435, United States
  • Minnesota Oncology Hematology, P.A
    Maplewood, Minnesota 55109, United States
  • Minnesota Oncology Hematology, P.A
    Minneapolis, Minnesota 55404, United States
  • Minnesota Oncology Hematology, P.A
    Saint Paul, Minnesota 55102, United States
  • St. Dominic- Jackson Memorial Hospital Pharmacy Attn: Richard Wakefield
    Jackson, Mississippi 39216, United States
  • Washington University School of Medicine- Obstetrics & Gynecology [Academic Offices]
    St Louis, Missouri 63108, United States
  • Washington University School of Medicine [Patient Clinics]
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine-Obstetrics & Gynecology
    St Louis, Missouri 63110, United States
  • NewYork Presbyterian - Brooklyn Methodist Hospital
    Brooklyn, New York 11215, United States
  • NewYork Presbyterian - Queens
    Flushing, New York 11355, United States
  • NewYork Presbyterian - Queens
    Forest Hills, New York 11375, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone.
    New York, New York 10016, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Fail·view Hospital
    Cleveland, Ohio 44111, United States
  • Cleveland Clinic Fairview Hospital- Moll Cancer Center lnvestigational Pharmacy
    Cleveland, Ohio 44111, United States
  • Cleveland Clinic Fairview Hospital
    Cleveland, Ohio 44111, United States
  • Cleveland Clinic.
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • OSU Wexner Medical Center, OSU Gynecologic Oncology at Mill Run
    Hilliard, Ohio 43026, United States
  • Cleveland Clinic Hillcrest Hospital
    Mayfield Heights, Ohio 44124, United States
  • Texas Oncology - Fort Worth Cancer Center
    Fort Worth, Texas 76104, United States
  • US Oncology lnvestigational Products Center (IPC)
    Irving, Texas 75063, United States
  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22903, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • VCU Health, Investigational Drug Service (ATTN: Henly Deutsch, RPh)
    Richmond, Virginia 23298, United States
  • Instituto Médico Especializado Alexander Fleming
    Buenos Aires, Buenos Aires F.D. C1426ANZ, Argentina
  • Sanatorio de la Mujer
    Rosario, Santa Fe Province CP 2000, Argentina
  • Fundacion CENIT para la lnvestigacion en Neurociencias
    Buenos Aires, C1125 ABD, Argentina
  • IONC - Instituto Oncologico de Cordoba
    Córdoba, ZC 5000, Argentina
  • Radiologie - Diagnosezentrum Urania
    Vienna, 1010, Austria
  • Cliniques Universitaires Saint Luc
    Brussels, Brabant 1200, Belgium
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
  • ZNA Middelheim
    Antwerp, 2020, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven-Campus Gasthuisberg
    Leuven, 3000, Belgium
  • CHU de Liege - Sart Tilman
    Liège, 4000, Belgium
  • CHU UCL Namur-Site St-Elisabeth
    Namur, 5000, Belgium
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia
    Ljui, Rio Grande do Sul 98700-000, Brazil
  • Hospital Mae de Deus
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Hospital de Sao Lucas da Pontificia Universidade CatoIica do Rio Grande do Sul -PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
    Porto Alegre, Rio Grande do Sul 90850-170, Brazil
  • A Beneficencia Portuguesa de Sao Paulo - BP Mirante
    São Paulo, São Paulo 01321-001, Brazil
  • Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner
    Curitiba/PR, 81520-060, Brazil
  • lnstituto Nacional de Cancer Jose Alencar Gomes da Silva - INCA- Coordenacao de Pesquisa Clinica
    Rio de Janeiro, 20220- 410, Brazil
  • CIPE Centro Internacional de Pesquisa - AC Camargo Cancer Center - CAPEC Centro de Apoio a Pesquisa
    São Paulo, 01509-010, Brazil
  • lnstituto Brasileiro de Controle do Cancer - IBCC
    São Paulo, 04014-002, Brazil
  • Cross Cancer Institute Cancer Committee
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer - Vancouver Center
    Vancouver, British Columbia V5Z 4E6, Canada
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Saskatoon Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430023, China
  • Hubei Cancer Hospital.
    Wuhan, Hubei, China
  • Union Hospital Affiliated to Tongji Medical College,Huazhong University of science and Technology
    Wuhan, Hubei, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital.
    Changsha, Hunan 410013, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First hospital of Jilin University
    Changchun, Jilin 130031, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110801, China
  • Shaanxi Provincial People's Hospital.
    Xi'an, Shaanxi 710068, China
  • Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital&Institute)
    Jinan, Shandong 250117, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 30001, China
  • The Shanxi Cancer Hospital
    Taiyuan, Shanxi 30013, China
  • Sichuan Cancer hospital
    Chengdu, Sichuan 610000, China
  • The Second People's Hospital of Yibin
    Yibin, Sichuan, China
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang Uygur Autonomous Region, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Cancer Hospital Chinese Academy of Medical Sciences (CAMS)
    Beijing, 100021, China

Showing the first 100 of 211 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yonemori K, Nishio S, Suzuki S, Hasegawa K, Yunokawa M, Yamaguchi S, Okamoto A, Nakamura K, Kamiura S, Fujiwara K, Katsumata N, Kobayashi H, Usami T, Mochizuki A, Takehara K, Whalley E, Noguchi H, Soumaoro I, Slomovitz B, Vergote I. Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial. Int J Gynecol Cancer. 2026 Apr;36(4):104450. doi: 10.1016/j.ijgc.2025.104450. Epub 2025 Dec 31. PubMed 41644383 ↗
  • Vergote I, Gonzalez-Martin A, Fujiwara K, Kalbacher E, Bagameri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. PubMed 38959480 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jul 2023, 29 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 29 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2021
First posted
Jan 6, 2021
StartActual
Feb 22, 2021
Primary completionActual
Jul 24, 2023
CompletionActual
Jan 15, 2026
Results first posted
Aug 9, 2024
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04697628
Collaborators
Genmab
Responsible party
Sponsor
First posted
Jan 6, 2021
Start date
Feb 22, 2021
Primary completion
Jul 24, 2023
Completion
Jan 15, 2026
Results posted
Aug 9, 2024
Last update
Feb 24, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion